Adverse effects of antiretroviral therapy

Antiretroviral toxicity is an increasingly important issue in the management of HIV-infected patients. With the sustained major declines in opportunistic complications, HIV infection is a more chronic disease, and so more drugs are being used in more patients for longer periods. This review focuses on the pathogenesis, clinical features, and management of the principal toxicities of the 15 licensed antiretroviral drugs, including mitochondrial toxicity, hypersensitivity, and lipodystrophy, as well as more drug-specific adverse effects and special clinical settings.

[1]  R. Stern,et al.  Severe adverse cutaneous reactions to drugs. , 1994, The New England journal of medicine.

[2]  E. Orringer,et al.  Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. , 1997, Clinical science.

[3]  Morris Schambelan,et al.  “Buffalo hump” in men with HIV-1 infection , 1998, The Lancet.

[4]  R. Stern,et al.  Cutaneous disease and drug reactions in HIV infection. , 1993, The New England journal of medicine.

[5]  O. Rouvière,et al.  A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. , 1999, AIDS.

[6]  K. Miller,et al.  Visceral abdominal-fat accumulation associated with use of indinavir , 1998, The Lancet.

[7]  D. Cooper,et al.  A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome , 2000, AIDS.

[8]  K. Henry,et al.  Severe premature coronary artery disease with protease inhibitors , 1998, The Lancet.

[9]  J. Smeitink,et al.  Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway , 1998, AIDS.

[10]  M. Dalakas,et al.  Mitochondrial toxicity of antiviral drugs , 1995, Nature Medicine.

[11]  J. Beijnen,et al.  The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. , 1999, AIDS.

[12]  K. Yarasheski,et al.  Insulin resistance in HIV protease inhibitor-associated diabetes. , 1999, Journal of acquired immune deficiency syndromes.

[13]  M. Sadler,et al.  Peripheral Neuropathy with Nucleoside Antiretrovirals , 1998, Drug safety.

[14]  D. Cooper,et al.  Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.

[15]  L. Ostrosky-Zeichner,et al.  Liposuction for protease-inhibitorassociated lipodystrophy , 1999, The Lancet.

[16]  J. Lisziewicz,et al.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.

[17]  D. Vlahov,et al.  Can HIV epidemics among injection drug users be prevented? , 1998, AIDS.

[18]  D. Cooper,et al.  Pathogenesis and management of HIV-associated drug hypersensitivity. , 1995, AIDS clinical review.

[19]  K. Henry,et al.  Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities , 1998, The Lancet.

[20]  C. H. Chen,et al.  Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine. , 1989, The Journal of biological chemistry.

[21]  S. Matheron,et al.  Alopecia associated with indinavir therapy. , 1999, The New England journal of medicine.

[22]  D Johnson,et al.  The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. , 1999, AIDS.

[23]  A. Telenti,et al.  Changes in renal function associated with indinavir , 1998, AIDS.

[24]  A. Fattorossi,et al.  Protective actions of L-carnitine and acetyl-L-carnitine on the neurotoxicity evoked by mitochondrial uncoupling or inhibitors. , 1995, Pharmacological research.

[25]  J. Touraine,et al.  The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. , 1999, AIDS.

[26]  L. Liaudet.  Severe ergotism associated with interaction between ritonavir and ergotamine , 1999, BMJ.

[27]  J. Lennox,et al.  Benign symmetric lipomatosis associated with protease inhibitors , 1997, The Lancet.

[28]  N. Letvin,et al.  Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease , 1998, The Lancet.

[29]  G. Ippolito,et al.  Zidovudine toxicity in uninfected healthcare workers , 1997 .

[30]  C. Shikuma,et al.  Fasting hyperinsulinemia and increased waist-to-hip ratios in non-wasting individuals with AIDS. , 1999, AIDS.

[31]  P. Reiss,et al.  Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy , 1999, The Lancet.

[32]  J. Henry,et al.  Fatal interaction between ritonavir and MDMA , 1998, The Lancet.

[33]  D. Cooper,et al.  Lipodystrophy following antiretroviral therapy of primary HIV infection. , 2000, AIDS.

[34]  P. Vernazza,et al.  A placebo‐controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection , 1998 .

[35]  M. Moroni,et al.  Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. , 1999, AIDS.

[36]  D. Cooper,et al.  Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance , 1998, The Lancet.

[37]  D. Ho,et al.  A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. , 1998, The Journal of infectious diseases.

[38]  C. Bouchard,et al.  Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir. , 1998, The New England journal of medicine.

[39]  R. Pollard,et al.  Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. , 1998, Clinical therapeutics.

[40]  J. Angel,et al.  Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  R. Sperling,et al.  Safety of the maternal–infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study , 1998, AIDS.

[42]  A. Telenti,et al.  Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study , 1999, The Lancet.

[43]  D. Cooper,et al.  Immunohistological assessment of cutaneous drug hypersensitivity in patients with HIV infection , 1994, Clinical and experimental immunology.

[44]  J. Gatell,et al.  Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. , 1999, AIDS.

[45]  W. Gahl,et al.  Zidovudine‐induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage , 1994, Annals of neurology.

[46]  J. Falk,et al.  Lactic acidosis in critical illness , 1992, Critical care medicine.

[47]  David A. Cooper,et al.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors , 1998, AIDS.

[48]  F. Altice,et al.  Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. , 1999, AIDS.

[49]  R. Roubenoff,et al.  A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. , 1999, AIDS.

[50]  Dorothy Bray,et al.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial , 1999, The Lancet.

[51]  D. Vittecoq,et al.  Vascular complications associated with use of HIV protease inhibitors , 1998, The Lancet.

[52]  L. M. Lehman,et al.  A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. , 1995, The New England journal of medicine.

[53]  K. K. Lai,et al.  Fulminant hepatic failure associated with 2',3'-dideoxyinosine (ddI). , 1991, Annals of internal medicine.

[54]  H. Conjeevaram,et al.  Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. , 1995, The New England journal of medicine.

[55]  L. Sundstrom,et al.  A soluble factor produced by macrophages mediates the neurotoxic effects of HIV-1 Tat in vitro. , 1999, AIDS.

[56]  C. Pettinelli,et al.  Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. An AIDS Clinical Trials Group Study. , 1990, Annals of internal medicine.

[57]  C. Hendrix,et al.  Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. , 1997, The Journal of infectious diseases.

[58]  P. Rustin,et al.  Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues , 1999, The Lancet.

[59]  Hay,et al.  Increased bleeding in HIV‐positive Haemophiliacs treated with antiretroviral protease inhibitors , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[60]  F. Lori.  Hydroxyurea and HIV: 5 years later--from antiviral to immune-modulating effects. , 1999, AIDS.

[61]  M. Prince,et al.  Ritonavir, triglycerides, and pancreatitis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[62]  G. Bratt,et al.  Sudden cardiac death in a patient on 2 years of highly active antiretroviral treatment: a case report. , 1999, AIDS.

[63]  D. Cooper,et al.  Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor , 1997, The Lancet.

[64]  R. Chaisson,et al.  Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions , 1999, Annals of Internal Medicine.

[65]  J. Berger,et al.  Inhibition of adipocyte differentiation by HIV protease inhibitors. , 1999, The Journal of clinical endocrinology and metabolism.

[66]  R. Luzzati,et al.  Riboflavine and severe lactic acidosis , 1999, The Lancet.

[67]  H. Jürgens,et al.  Platelet Dysfunction as the Cause of Spontaneous Bleeding in Two Haemophilic Patients Taking HIV Protease Inhibitors , 1998, Thrombosis and Haemostasis.

[68]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.

[69]  D. Ilsley,et al.  3′-Azidothymidine (Zidovudine) Inhibits Glycosylation and Dramatically Alters Glycosphingolipid Synthesis in Whole Cells at Clinically Relevant Concentrations (*) , 1995, The Journal of Biological Chemistry.

[70]  D. Cooper,et al.  Gap between biology and reality in AIDS , 1998, The Lancet.

[71]  D. Ho,et al.  A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. , 1995, The New England journal of medicine.

[72]  P. Halfon,et al.  Metabolic, hepatic and muscular changes during zidovudine therapy: a drug-induced mitochondrial disease? , 1994, AIDS.

[73]  J. Currier,et al.  Protease inhibitor-associated hyperglycaemia , 1997, The Lancet.

[74]  J. Darbyshire,et al.  Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals , 1996, The Lancet.

[75]  J. Montaner,et al.  Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS) , 1990, Annals of internal medicine.

[76]  D. Cooper,et al.  Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS. , 1993, The Journal of infectious diseases.

[77]  J. Miro,et al.  Influence of environmental temperature on incidence of indinavir-related nephrolithiasis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[78]  T. Cihlar,et al.  The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. , 1999, Molecular pharmacology.

[79]  E. Furfine,et al.  Stimulation of vitamin A(1) acid signaling by the HIV protease inhibitor indinavir. , 2000, Biochemical pharmacology.

[80]  F. Goebel,et al.  Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV‐1‐infected patients , 1998, AIDS.

[81]  S. Hammer,et al.  A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. , 1996, The New England journal of medicine.

[82]  J. Groopman,et al.  Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine. , 1991, The American journal of medicine.

[83]  T. Brown,et al.  HIV risk behavioral surveillance: a methodology for monitoring behavioral trends. , 1998, AIDS.

[84]  P. Peterson,et al.  The treatment of mitochondrial myopathies and encephalomyopathies. , 1995, Biochimica et biophysica acta.

[85]  P. Sax,et al.  Variation in incidence of indinavir‐associated nephrolithiasis among HIV‐positive patients , 1998, AIDS.

[86]  I. Pike,et al.  Rates and risk factors for adverse events associated with didanosine in the expanded access program. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[87]  K Henry,et al.  The Case for More Cautious, Patient-Focused Antiretroviral Therapy , 2000, Annals of Internal Medicine.